Alexion vet Goff to lead Agios as CEO; Fouse becoming chair
Plus new CEOs at SpyBiotech, Centauri and Telix, and updates from Acelyrin and more
Two months after announcing a restructuring plan and a shift in focus away from exploratory research and drug discovery to late lead optimization, Agios Pharmaceuticals Inc. (NASDAQ:AGIO) is getting a new CEO in Brian Goff, who will succeed Jackie Fouse on August 8. Goff was EVP, chief commercial and global operations officer at Alexion Pharmaceuticals Inc., before its acquisition by AstraZeneca plc (LSE:AZN; NASDAQ:AZN) in July 2021. Fouse will become chair, succeeding David Schenkein, who will remain on the board. CSO Bruce Car is leaving the company on July 31.
British biotechnology company SpyBiotech Ltd. named Mark Leuchtenberger as CEO and a director, and Sumi Biswas as CSO. Leuchtenberger was executive chairman at Aleta Biotherapeutics Inc. and CEO at Brooklyn ImmunoTherapeutics Inc. (NYSE:BTX). Biswas co-founded SpyBiotech in 2017, and remains president and director at the company...